Emergent BioSolutions Wins $22.3M Contract from U.S. Department of War
Emergent BioSolutions received a $22.3 million modification exercising an option under an existing IDIQ contract to supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War. Deliveries will begin in 2026 with a $7.4 million initial shipment and continue through 2027 to support anthrax pre-exposure prophylaxis for all branches of the U.S. military.
Emergent BioSolutions reported total assets of $995.2 million as of September 30, 2026, a decrease from $1,318.6 million at year-end 2025. The company is navigating significant debt obligations under a new 2026 Term Loan Agreement and is focused on its medical countermeasure (MCM) contracts with the U.S. government and the commercial performance of NARCAN Nasal Spray.
Emergent BioSolutions reported Q3 2026 total revenues of $110.0 million, a 52% decrease year-over-year, and a net loss of $32.7 million. The results were primarily driven by the company's biodefense and naloxone portfolios as it continues a multi-year strategic transformation and turnaround.
Term
Q3 2026
“Emergent's third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medical countermeasures and naloxone portfolio, underscoring the importance of disciplined execution as we advance our multi-year transformation.”
Joe Papa, president and chief executive officer
“We remain focused on our turnaround priorities and strengthening our financial position, which includes improving operating performance, reducing debt, creating long-term shareholder value, continuously demonstrating high standards of quality and compliance in all we do and delivering on our mission to protect and save lives.”